Q2 2025 Sotera Health Co Earnings Call Transcript
Key Points
- Sotera Health Co (SHC) reported a strong second quarter with a 6.4% increase in revenue and a 9.8% growth in adjusted EBITDA.
- Sterigenics experienced a 10.5% year-over-year revenue growth, driven by increased customer demand and successful facility expansion.
- Nordion exceeded revenue expectations due to the timing of Cobalt-60 shipments, contributing positively to the quarter's performance.
- Nelson Labs achieved a 514 basis points expansion in segment income margin, marking the fourth consecutive quarter of year-over-year margin improvement.
- The company raised its 2025 revenue growth outlook to 4.5% to 6% and adjusted EBITDA growth outlook to 6% to 7.5%, reflecting improved performance expectations.
- Nelson Labs experienced a 3.3% decline in revenue compared to Q2 2024, primarily due to the anticipated impact from expert advisory services.
- Nordion's segment income margin decreased by 145 basis points due to the timing of supplier mix, despite an increase in revenue.
- The company is facing increased maintenance-related downtime in the second half of the year, which may affect growth.
- There is a potential risk associated with Russian-supplied Cobalt-60, although it has improved to less than 0.5% of total company 2025 revenue.
- The effective tax rate is projected to be relatively high, in the range of 31.5% to 33.5%, despite recent favorable changes in US tax law.
Good morning, and welcome to the Sotera Health Second Quarter 2025 Conference Call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Vice President and Treasurer, Jason Peterson. Please go ahead.
Good morning, and thank you. Welcome to Sotera Health's Second Quarter 2025 Earnings Call. You can find today's press release and accompanying supplemental slides on the Investors section of our website at soterahealth.com. This webcast is being recorded, and a replay will be available in the Investors section of the Sotera Health website.
On the call with me today are Chairman and Chief Executive Officer, Michael Petras, and Chief Financial Officer, Jon Lyons. During the call, some of our comments may be considered forward-looking statements. The matters addressed in these statements are subject to risks, uncertainties that could cause actual results to differ materially from those projected or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
